MX384246B - POLIPÉPTIDO DE UNIÓN A TCR ALFA BETA PARA USARSE EN LA DISMINUCIÓN DE LINFOCITOS TAß. - Google Patents

POLIPÉPTIDO DE UNIÓN A TCR ALFA BETA PARA USARSE EN LA DISMINUCIÓN DE LINFOCITOS TAß.

Info

Publication number
MX384246B
MX384246B MX2016005687A MX2016005687A MX384246B MX 384246 B MX384246 B MX 384246B MX 2016005687 A MX2016005687 A MX 2016005687A MX 2016005687 A MX2016005687 A MX 2016005687A MX 384246 B MX384246 B MX 384246B
Authority
MX
Mexico
Prior art keywords
methods
binding polypeptide
immunosuppressive therapy
humanized
alpha beta
Prior art date
Application number
MX2016005687A
Other languages
English (en)
Other versions
MX2016005687A (es
Inventor
Andreas Menrad
Daniel Snell
Gina Lacorcia
Gregor Blank
Karin Schilbach
Rupert Handgretinger
Original Assignee
Genzyme Corp
Univ Eberhard Karls Tuebingen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Univ Eberhard Karls Tuebingen filed Critical Genzyme Corp
Publication of MX2016005687A publication Critical patent/MX2016005687A/es
Publication of MX384246B publication Critical patent/MX384246B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos mejorados para uso de un polipéptido de unión humanizado específico para el receptor de linfocitos T alfa beta (aß-TCR). En particular, esta descripción está relacionada con métodos mejorados de uso de un anticuerpo anti-aß-TCR humanizado, que deriva del anticuerpo monoclonal murino BMA031, en terapia inmunosupresora. También se proporcionan métodos nuevos usando anticuerpos monoclonales humanizados y/o fragmentos de anticuerpo monoclonal humanizado (por ejemplo, anticuerpos anti-aßTCR y/o fragmentos de los mismos). Se proporcionan métodos nuevos que usan administración repetida de anticuerpos monoclonales humanizados y/o fragmentos de anticuerpos monoclonales humanizados (por ejemplo, anticuerpos anti-aßTCR y/o fragmentos de los mismos) para reducir linfocitos T aß en el sujeto en relación con linfocitos T yd en el sujeto.
MX2016005687A 2013-10-30 2014-10-30 POLIPÉPTIDO DE UNIÓN A TCR ALFA BETA PARA USARSE EN LA DISMINUCIÓN DE LINFOCITOS TAß. MX384246B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361897809P 2013-10-30 2013-10-30
PCT/US2014/063254 WO2015066379A2 (en) 2013-10-30 2014-10-30 Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide

Publications (2)

Publication Number Publication Date
MX2016005687A MX2016005687A (es) 2017-03-30
MX384246B true MX384246B (es) 2025-03-14

Family

ID=52021413

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005687A MX384246B (es) 2013-10-30 2014-10-30 POLIPÉPTIDO DE UNIÓN A TCR ALFA BETA PARA USARSE EN LA DISMINUCIÓN DE LINFOCITOS TAß.

Country Status (8)

Country Link
US (2) US11142575B2 (es)
EP (1) EP3063174B1 (es)
CN (1) CN106795220A (es)
AU (2) AU2014342182B2 (es)
CA (1) CA2928756A1 (es)
MX (1) MX384246B (es)
SG (2) SG10201803473WA (es)
WO (1) WO2015066379A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
AU2014342182B2 (en) * 2013-10-30 2020-05-14 Eberhard Karls Universitat Tubingen Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta TCR -binding polypeptide
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
WO2017049159A1 (en) * 2015-09-16 2017-03-23 Ledebur Jr Harry C T-CELL RECEPTOR (TCR) TARGETING THERAPIES FOR IMMUNE-MEDIATED ADVERSE DRUG REACTIONS (ADRs) AND OTHER CONDITIONS
CN108070644B (zh) * 2016-11-08 2021-06-29 国家卫生计生委科学技术研究所 一种妊娠高血压的诊断系统
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
EP3650539A4 (en) * 2017-07-07 2021-08-18 Hanmi Pharm. Co., Ltd. NEW THERAPEUTIC ENZYMFUSION PROTEIN AND ITS USAGE
CN109777778B (zh) * 2017-11-14 2023-07-18 中国科学院广州生物医药与健康研究院 一种基因改造的γδT细胞
DE102017127984B4 (de) * 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
MA55529A (fr) * 2019-04-03 2022-02-09 Genzyme Corp Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
JP7590430B2 (ja) * 2019-11-14 2024-11-26 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CR20230263A (es) 2020-12-17 2023-08-21 Hoffmann La Roche Anticuerpos anti-hla-g y uso de estos
BR112023022975A2 (pt) 2021-05-05 2024-01-23 Immatics Biotechnologies Gmbh Polipeptídeos de ligação ao antígeno bma031 melhorados
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy
CN118108842A (zh) * 2023-06-09 2024-05-31 浙江大学 人源化抗cd24抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20050058641A1 (en) * 2002-05-22 2005-03-17 Siemionow Maria Z. Tolerance induction and maintenance in hematopoietic stem cell allografts
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
AU2007345745C1 (en) 2006-06-19 2013-05-23 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
CN101636168B (zh) 2007-01-09 2013-05-29 比奥根艾迪克Ma公司 Sp35抗体及其用途
AU2009288354A1 (en) 2008-08-26 2010-03-11 Macrogenics Inc. T-cell receptor antibodies and methods of use thereof
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9018006B2 (en) * 2010-07-23 2015-04-28 The University Of Toledo Stable Tregs and related materials and methods
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
AU2014342182B2 (en) * 2013-10-30 2020-05-14 Eberhard Karls Universitat Tubingen Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta TCR -binding polypeptide

Also Published As

Publication number Publication date
EP3063174A2 (en) 2016-09-07
AU2014342182B2 (en) 2020-05-14
AU2020217395A1 (en) 2020-09-03
SG11201603193PA (en) 2016-05-30
US11142575B2 (en) 2021-10-12
WO2015066379A3 (en) 2015-07-09
US20220098299A1 (en) 2022-03-31
SG10201803473WA (en) 2018-06-28
AU2014342182A1 (en) 2016-05-19
CA2928756A1 (en) 2015-05-07
CN106795220A (zh) 2017-05-31
EP3063174B1 (en) 2020-12-09
US20160244523A1 (en) 2016-08-25
MX2016005687A (es) 2017-03-30
WO2015066379A2 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
SG10201803473WA (en) Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
PH12020500368A1 (en) B7-h4 antibodies and methods of use thereof
WO2014011988A3 (en) Enhancing activity of car t cells by co-introducing a bispecific antibody
PH12020500677A1 (en) Neoantigens and uses thereof
MY190711A (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
CR20200014A (es) Molécula de polipéptido con especificidad dual mejorada
AU2014236098A8 (en) Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
MX2020003046A (es) Anticuerpos anti-hla-a2 y metodos para utilizar los mismos.
PH12017500268A1 (en) Antibodies and chimeric antigen receptors specific for cd19
TN2013000076A1 (en) Anti-ox40 antibodies and methods of using the same
EP3593812A3 (en) Treatment of cancer using chimeric antigen receptor
MX357193B (es) Moleculas de union anti-alfa sinucleina.
NZ628314A (en) Cd47 antibodies and methods of use thereof
HK1207655A1 (en) Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
MX2015014017A (es) Variante de la region fc.
MX2013005015A (es) Anticuerpos anti-il-23.
MX2015003150A (es) Anticuerpos específicos de polipeptido amiloide de islote humano (hiapp) y sus usos.
PL422231A1 (pl) Komórki immunologiczne CAR do leczenia nowotworów
MX2018016121A (es) Preparacion de anticuerpos monoclonales marcados con 212pb.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
WO2019112347A3 (ko) 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도
MX2016001383A (es) Metodos para reducir la tasa de exacerbacion de asma mediante el uso de benralizumab.
MY187971A (en) Antibody constructs for cd70 and cd3
WO2012106669A3 (en) Foxc1 antibodies and methods of their use
HK1227898A1 (en) Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide